What are you using as reference if you think 200 million is a few number of outstanding shares? IMO you are failing to take into account the need to fund multiple clinical trials with many more patients and clinical sites. As I mentioned previously, the CEO's statements are of little consequence as he should be willing to change his views based on the companies best interests. You should be more concerned with a CEO that forces his own agenda without fully considering the benefit of such a decision.
News 
Market Data 
Discover 
